Sanofi
ISIN: FR0000120578 | Ticker: SAN | LEI: 549300E9PC51EN656011
Country: France
Sanofi S.A. is a French multinational healthcare company headquartered in Paris, France. Originally, the corporation was established in 1973 and merged with Synthélabo in 1999 to form Sanofi-Synthélabo. In 2004, Sanofi-Synthélabo merged with Aventis and renamed to Sanofi-Aventis, which were each the product of several previous mergers. Sanofi engages in the research and development, manufacturing and marketing of pharmaceutical drugs principally in the prescription market, but the firm also develops over-the-counter medication. The corporation covers seven major therapeutic areas: cardiovascular, central nervous system, diabetes, internal medicine, oncology, thrombosis and vaccines (it is the world's largest producer of the latter through its subsidiary Sanofi Pasteur).
Year founded1973
Served areaWorldwide
Headcount100,000
Headquarters54 Rue la Boétie, 75008 Paris – France
| Line item in (eur) | 01.01.2019 | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|---|---|
| Assets | N/A | 112,630,000,000.00 | 114,413,000,000.00 | 120,242,000,000.00 | 126,722,000,000.00 |
| Noncurrent Assets | N/A | 83,694,000,000.00 | 80,627,000,000.00 | 89,589,000,000.00 | 92,611,000,000.00 |
| Property Plant And Equipment | N/A | 9,717,000,000.00 | 9,365,000,000.00 | 10,028,000,000.00 | 9,869,000,000.00 |
| Goodwill | N/A | 44,519,000,000.00 | 44,364,000,000.00 | 48,056,000,000.00 | 49,892,000,000.00 |
| Intangible Assets Other Than Goodwill | N/A | 16,509,000,000.00 | 18,341,000,000.00 | 21,407,000,000.00 | 21,640,000,000.00 |
| Investment Accounted For Using Equity Method | N/A | 3,591,000,000.00 | 201,000,000.00 | 250,000,000.00 | 677,000,000.00 |
| Deferred Tax Assets | N/A | 5,391,000,000.00 | 4,176,000,000.00 | 4,598,000,000.00 | 5,381,000,000.00 |
| Current Tax Assets Noncurrent | N/A | 164,000,000.00 | 248,000,000.00 | 175,000,000.00 | 242,000,000.00 |
| Other Noncurrent Assets | N/A | 2,503,000,000.00 | 2,734,000,000.00 | 3,127,000,000.00 | 3,095,000,000.00 |
| Inventories | N/A | 7,994,000,000.00 | 8,352,000,000.00 | 8,715,000,000.00 | 8,960,000,000.00 |
| Current Trade Receivables | N/A | 7,937,000,000.00 | 7,491,000,000.00 | 7,568,000,000.00 | 8,424,000,000.00 |
| Current Tax Assets Current | N/A | 808,000,000.00 | 1,208,000,000.00 | 612,000,000.00 | 374,000,000.00 |
| Cash and cash equivalents | 6,925,000,000.00 | 9,427,000,000.00 | 13,915,000,000.00 | 10,098,000,000.00 | 12,736,000,000.00 |
| Current Assets Other Than Assets Or Disposal Groups Classified As Held For Sale Or As Held For Distribution To Owners | N/A | 28,611,000,000.00 | 33,703,000,000.00 | 30,564,000,000.00 | 34,026,000,000.00 |
| Noncurrent Assets Or Disposal Groups Classified As Held For Sale | N/A | 325,000,000.00 | 83,000,000.00 | 89,000,000.00 | 85,000,000.00 |
| Other Current Assets | N/A | 2,445,000,000.00 | 2,737,000,000.00 | 3,571,000,000.00 | 3,532,000,000.00 |
| Equity And Liabilities | N/A | 112,630,000,000.00 | 114,413,000,000.00 | 120,242,000,000.00 | 126,722,000,000.00 |
| Equity | 59,175,000,000.00 | 59,230,000,000.00 | 63,252,000,000.00 | 69,031,000,000.00 | 75,152,000,000.00 |
| Equity Attributable To Owners Of Parent | N/A | 59,056,000,000.00 | 63,106,000,000.00 | 68,681,000,000.00 | 74,784,000,000.00 |
| Noncontrolling Interests | N/A | 174,000,000.00 | 146,000,000.00 | 350,000,000.00 | 368,000,000.00 |
| Noncurrent Liabilities | N/A | 33,013,000,000.00 | 31,881,000,000.00 | 29,916,000,000.00 | 27,596,000,000.00 |
| Deferred Tax Liabilities | N/A | 2,294,000,000.00 | 1,770,000,000.00 | 1,617,000,000.00 | 1,841,000,000.00 |
| Current Tax Liabilities Noncurrent | N/A | 1,680,000,000.00 | 1,733,000,000.00 | 2,039,000,000.00 | 1,979,000,000.00 |
| Longterm Borrowings | N/A | 20,131,000,000.00 | 19,745,000,000.00 | 17,123,000,000.00 | 14,857,000,000.00 |
| Trade And Other Current Payables To Trade Suppliers | N/A | 5,313,000,000.00 | 5,295,000,000.00 | 6,180,000,000.00 | 6,813,000,000.00 |
| Current Tax Liabilities Current | N/A | 258,000,000.00 | 604,000,000.00 | 309,000,000.00 | 574,000,000.00 |
| Current Liabilities Other Than Liabilities Included In Disposal Groups Classified As Held For Sale | N/A | 20,381,000,000.00 | 19,248,000,000.00 | 21,295,000,000.00 | 23,964,000,000.00 |
| Liabilities Included In Disposal Groups Classified As Held For Sale | N/A | 6,000,000.00 | 32,000,000.00 | 0.00 | 10,000,000.00 |
| Current Borrowings And Current Portion Of Noncurrent Borrowings | N/A | 4,554,000,000.00 | 2,767,000,000.00 | 3,183,000,000.00 | 4,174,000,000.00 |
| Line item in (eur) | 01.01.2019/ 01.01.2020 |
01.01.2020/ 01.01.2021 |
01.01.2021/ 01.01.2022 |
01.01.2022/ 01.01.2023 |
|---|---|---|---|---|
| Revenue From Sale Of Goods | 36,126,000,000.00 | 36,041,000,000.00 | 37,761,000,000.00 | 42,997,000,000.00 |
| Other Revenue | 1,505,000,000.00 | 1,328,000,000.00 | 1,414,000,000.00 | 2,392,000,000.00 |
| Profit Loss From Operating Activities | 3,051,000,000.00 | 14,113,000,000.00 | 8,126,000,000.00 | 10,656,000,000.00 |
| Finance Income | 141,000,000.00 | 53,000,000.00 | 40,000,000.00 | 206,000,000.00 |
| Finance Costs | 440,000,000.00 | 388,000,000.00 | 368,000,000.00 | 440,000,000.00 |
| Income Tax Expense Continuing Operations | 121,000,000.00 | 1,807,000,000.00 | 1,558,000,000.00 | 2,006,000,000.00 |
| Profit Loss From Continuing Operations | 2,886,000,000.00 | 12,330,000,000.00 | 6,279,000,000.00 | N/A |
| Profit Loss From Discontinued Operations | -101,000,000.00 | 0.00 | 0.00 | N/A |
| Profit (loss) | 2,785,000,000.00 | 12,330,000,000.00 | 6,279,000,000.00 | 8,484,000,000.00 |
| Profit Loss Attributable To Owners Of Parent | 2,754,000,000.00 | 12,294,000,000.00 | 6,223,000,000.00 | 8,371,000,000.00 |
| Profit Loss Attributable To Noncontrolling Interests | 31,000,000.00 | 36,000,000.00 | 56,000,000.00 | 113,000,000.00 |
| Line item in (eur) | 01.01.2019 | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|---|---|
| Profit (loss) | N/A | 2,785,000,000.00 | 12,330,000,000.00 | 6,279,000,000.00 | 8,484,000,000.00 |
| Adjustments For Decrease Increase In Inventories | N/A | -547,000,000.00 | -593,000,000.00 | -357,000,000.00 | -927,000,000.00 |
| Adjustments For Increase Decrease In Trade Account Payable | N/A | 169,000,000.00 | 86,000,000.00 | 451,000,000.00 | 452,000,000.00 |
| Adjustments For Sharebased Payments | N/A | 252,000,000.00 | 274,000,000.00 | 244,000,000.00 | 245,000,000.00 |
| Adjustments For Losses Gains On Disposal Of Noncurrent Assets | N/A | -286,000,000.00 | -301,000,000.00 | -300,000,000.00 | -711,000,000.00 |
| Other Adjustments To Reconcile Profit Loss | N/A | -309,000,000.00 | -711,000,000.00 | -57,000,000.00 | 138,000,000.00 |
| Interest Paid Classified As Operating Activities | N/A | 379,000,000.00 | 315,000,000.00 | 334,000,000.00 | 380,000,000.00 |
| Interest Received Classified As Operating Activities | N/A | 92,000,000.00 | 37,000,000.00 | 3,000,000.00 | 173,000,000.00 |
| Income Taxes Paid Refund Classified As Operating Activities | N/A | 1,695,000,000.00 | 2,051,000,000.00 | 1,280,000,000.00 | 2,452,000,000.00 |
| Cash Flows From Used In Operating Activities | N/A | 7,715,000,000.00 | 7,418,000,000.00 | 10,522,000,000.00 | 10,526,000,000.00 |
| Cash Flows From Losing Control Of Subsidiaries Or Other Businesses Classified As Investing Activities | N/A | N/A | 0.00 | 42,000,000.00 | 134,000,000.00 |
| Cash Flows Used In Obtaining Control Of Subsidiaries Or Other Businesses Classified As Investing Activities | N/A | 488,000,000.00 | 5,336,000,000.00 | 5,594,000,000.00 | 992,000,000.00 |
| Cash Flows From Used In Investing Activities | N/A | -1,183,000,000.00 | 3,619,000,000.00 | -7,298,000,000.00 | -2,075,000,000.00 |
| Payments From Changes In Ownership Interests In Subsidiaries | N/A | 7,000,000.00 | 0.00 | 0.00 | N/A |
| Proceeds From Issuing Shares | N/A | 162,000,000.00 | 203,000,000.00 | 186,000,000.00 | 188,000,000.00 |
| Payments To Acquire Or Redeem Entitys Shares | N/A | 9,000,000.00 | 822,000,000.00 | 382,000,000.00 | 497,000,000.00 |
| Payments Of Lease Liabilities Classified As Financing Activities | N/A | 267,000,000.00 | 234,000,000.00 | 149,000,000.00 | 291,000,000.00 |
| Cash Flows From Used In Financing Activities | N/A | -4,193,000,000.00 | -6,485,000,000.00 | -7,056,000,000.00 | -5,821,000,000.00 |
| Effect Of Exchange Rate Changes On Cash And Cash Equivalents | N/A | 9,000,000.00 | -64,000,000.00 | 15,000,000.00 | 8,000,000.00 |
| Increase (decrease) in cash and cash equivalents after effect of exchange rate changes | N/A | 2,502,000,000.00 | 4,488,000,000.00 | -3,817,000,000.00 | 2,638,000,000.00 |
| Cash and cash equivalents | 6,925,000,000.00 | 9,427,000,000.00 | 13,915,000,000.00 | 10,098,000,000.00 | 12,736,000,000.00 |
Please note that some sums might not add up.
| Date | Trading entity / Person | Association | Trade type | Volume |
|---|---|---|---|---|
| 09.06.23 | None | Other | Buy | EUR 856.04 |
| 02.05.23 | None | Other | Buy | EUR 48,835.00 |
FR0000120578
LEI549300E9PC51EN656011
SectorPharmaceuticals, Biotechnology & Life Sciences
IndustryCAC40
Main Stock ExchangeKeep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.